Teleflex Incorporated (NYSE:TFX) posted its earnings results on Thursday. The medical technology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11, Bloomberg Earnings reports. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The firm had revenue of $534.70 million during the quarter, compared to analyst estimates of $522.94 million. During the same period last year, the firm posted $1.80 earnings per share. Teleflex’s revenue for the quarter was up 17.3% compared to the same quarter last year. Teleflex updated its FY17 guidance to $8.30-8.40 EPS.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.54%. The ex-dividend date is Tuesday, November 14th. Teleflex’s payout ratio is 26.00%.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/teleflex-incorporated-tfx-releases-earnings-results-beats-expectations-by-0-12-eps.html.

A number of research analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of Teleflex from $237.00 to $285.00 and gave the company a “buy” rating in a report on Friday. Zacks Investment Research lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Stephens reissued a “buy” rating and issued a $270.00 target price (up from $230.00) on shares of Teleflex in a report on Monday, September 25th. Deutsche Bank AG reissued a “buy” rating and issued a $251.00 target price (up from $238.00) on shares of Teleflex in a report on Monday, September 18th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $253.00 price objective (up from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $266.75.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $211.75, for a total value of $42,350.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at approximately $1,710,940. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 2.39% of the stock is owned by corporate insiders.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.